AI Dermatology Case Study | 98.5% Accuracy with AWS GenAI | ITTStar

Executive Summary

In the dynamic healthcare technology sector, GenerateMD, a pioneer in dermatological screening services, transformed their operations through an AI-powered platform called GenerateMD, powered by Amazon Bedrock Nova Pro. This platform harnesses AWS's scalable cloud infrastructure and advanced Generative AI capabilities, enabling multimodal reasoning, detailed image interpretation, and natural-language synthesis. Using GenAI models, GenerateMD delivers highly accurate, instantaneous skin disease diagnosis, enabling healthcare providers to expand patient care while drastically reducing costs and operational time.
The solution’s automation and Generative AI–driven insights ensure more efficient processing, increased diagnostic precision, and accessibility to underserved populations. These GenAI features allow the system to simulate dermatologist-level reasoning, craft human-like medical explanations, and standardize diagnostic quality at scale.

Customer Challenges in Dermatological Screening

• Limited Access and Scalability:GenerateMD’s manual screening processes limited patient throughput to 25–30 per dermatologist daily, creating six-week wait times and leaving thousands on waiting lists.

• High Costs and Resource Constraints:Manual consultations cost $200–300 each, leading to a 40% patient dropout rate and consuming 62% of service revenue on specialist salaries.

• Inconsistent Diagnostic Accuracy:Diagnostic accuracy among practitioners varied widely (60–75%), with no standard protocols and missed early-detection opportunities.

• Data Consolidation Difficulties:Patient data was dispersed and inconsistent, adversely affecting diagnostic precision across the network.

• Time and Resource Inefficiencies:The combination of high demand and limited specialist availability resulted in significant annual revenue losses and market share erosion.

ITTStar’s Solution

To address these challenges, ITTStar implemented GenerateMD, an AI-driven dermatological screening platform integrating Amazon Bedrock Nova Pro with AWS services such as Lambda, S3, API Gateway, CloudWatch, and IAM for secure, scalable, and cost-efficient operations.
The platform leverages Generative AI Models for multimodal medical analysis, enabling dermatologist-level interpretation based on image patterns, contextual reasoning, and medical domain knowledge. Core features include:

• Multi-Lesion Detection:Allowing simultaneous identification of multiple skin conditions in a single image using GenAI-based visual inference.

• Real-Time Diagnostic Analysis:Completed in under 3 seconds, driven by Bedrock’s optimized inference engine.

• Automated Generation of Professional PDF Reports:With visual and textual medical recommendations using GenAI-powered summarization and medical-grade explanation synthesis.

• HIPAA-Compliant Data Storage:With end-to-end encryption and comprehensive audit trails.

• Always-On Cloud Infrastructure:Enabling unlimited, scalable screening capacity.

• API-First Design:Facilitating seamless integration into existing healthcare ecosystems.

Implementation

• Assessment and Planning:Collaborative requirement gathering, AWS service selection, security framework design, and data strategy formulation. Additional emphasis was placed on mapping clinical workflows to Generative AI use cases to ensure accurate medical reasoning and alignment with dermatological standards.

• Development and Testing:AI model integration, responsive web UI development, security implementation, and performance optimization. Generative AI pipelines were rigorously tested to validate image-to-text accuracy, condition classification reliability, and report-generation quality.

• Production Deployment:Infrastructure provisioning via CloudFormation, HIPAA compliance validation, load testing, and go-live support.

Business and Technical Outcomes

• 98% Cost Reduction:In screening expenses, decreasing cost per analysis from $250 to $5.94.

• Diagnostic Accuracy Improved to 98.5%:A 51% gain from baseline manual methods, driven by GenAI’s ability to standardize clinical reasoning.

• Analysis Time Reduced by 99.8%:From 30 minutes to under 3 seconds through Generative AI–based rapid inference.

• Expanded Service Capacity:From 1,000 to unlimited annual consultations across two states.

• Improved Patient Access:With 65% of new patients coming from previously underserved areas.

• Early Detection Rates Increased by 23%:Significantly improving overall health outcomes.

Why AWS?

AWS was selected for its HIPAA-compliant, secure, and scalable infrastructure, providing a robust environment for processing sensitive medical data. Amazon Bedrock Nova Pro offers advanced Generative AI capabilities tailored for healthcare imaging with extensive token context windows for multimodal data.
Serverless AWS Lambda auto-scales to meet demand efficiently, while Amazon S3 ensures secure storage. The combination of API Gateway and CloudWatch enables reliable integrations and real-time monitoring, making AWS an ideal platform to support GenerateMD’s growth and innovation.

Why GenerateMD Chose ITTStar

GenerateMD selected this AWS-powered AI platform for its rapid deployment (6 weeks vs. months with traditional methods), significant cost savings, and superior diagnostic accuracy.
The scalable serverless architecture and built-in compliance features minimized risk and maximized operational efficiency. The incorporation of Generative AI medical reasoning and automated report synthesis positioned GenerateMD as a market leader in AI-based dermatological screening.

Results & Impact Summary

• Drastic cost reduction with sustainable scalability.
• Market expansion and increased patient access with superior care quality.
• Enhanced provider satisfaction and reduced churn.s.
• Demonstrated technology leadership within the healthcare market.
• Scalable architecture for multi-clinic expansion.

This case exemplifies how integrating AWS Generative AI services can revolutionize healthcare screening by delivering precise, efficient, and accessible solutions, driving measurable business and clinical outcomes for GenerateMD.